摘要
目的研究CPT-11联合CAP和5-Fu/CF方案治疗晚期大肠癌的近期疗效和毒副反应。方法经病理组织学诊断的晚期大肠癌77例随机分成两组,实验组39例,用CPT-11100mg/m^2,静脉滴注90分钟,d1,d8;CAP1000mg/m^2,2次/天,d1—14口服;对照组38例,给予5-Fu400mg/m^2,d1,d2,静脉滴人,5-Fu600mg/m^2,微量泵泵人48h以上。21天为一个周期,治疗2个周期后评定疗效。结果实验组39例总有效率为48.7%(19例),对照组38例总有效率为21.1%(8例),差异有统计学意义(P〈0.025)。主要毒副反应为迟发性腹泻,而血液学毒性、消化道副反应及肝肾毒性、脱发等相对轻微,无治疗相关性死亡患者。结论CPT-11联合CAP治疗晚期大肠癌疗效明显优于5-Fu/CF,值得临床推广使用。
Objective To compare the recently curative, noxious and side effects of drug combination of CPT - 11 plus CAP and 5 - Fu/CF in the treatment of advanced colorectal cancer. Methods 77 cases of advanced colorectal cancer diagnosed by pathology and histology were divided into 2 groups randomly. Experimental group (39 cases) :CPT - 11 100 mg/m^2 was injected in 90 minutes in d 1, 8, capecitabine 1 000 mg/m^2 was taken twice a day in dl - 14. Control group(38 cases) :CF 200 mg was injected in d1,2,foUowed by the injection of 5 - Fu 400 mg/m^2 in d1,2 and the micro pumping of 5 - Fu 600 mg/m^2 over 48 hours in d2. The treatment was repeated every three weeks as one cycle and the treatment effect was evaluated after 2 cycles. Results The total effective rates of experimental group(39 cases)and control group (38 cases)are 48.7% (19cases)and 21.1% (8 cases), respectively. There is statistical significance between the two groups( P 〈 0. 025 ). The main noxious and side effects were delayed diarrhea, leucopenia, nausea and vomiting, etc. There was no treatment related death. Conclusion The curative effect of drug combination of CPT - 11 plus CAP is superior to 5 - Fu/CF in the treatment of advanced colorectal cancer and the combination was recommended to be used widely.
出处
《实用肿瘤学杂志》
CAS
2009年第4期336-338,362,共4页
Practical Oncology Journal
关键词
伊立替康
卡培他滨
5-FU
晚期大肠癌
Irinotecan(CPT-11)
Capecitabine(CAP)
5 -Fu
Advanced colorectal cancer